About Vor Biopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.vorbio.com/
Frequently Asked Questions
What is the 52-week range for VOR?
The 52-week high is $42.75 and the 52-week low is $6.5.
What is the P/E ratio for VOR?
The Price to Earnings (P/E) ratio is 1.73.
What is the dividend yield for VOR?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -142.13%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.79.
Analyst Recommendation Trends
Wall Street analyst consensus for VOR over the last few months:
Latest VOR News
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
More than 94% of participants achieved a ≥5-point MG-ADL improvement at Week 48 42% of telitacicept-treated participants achieved minimal symptom expression (MSE) at any time over 48 weeks, increasing from 23.7% over the first 24 weeks After achieving MSE, 86.7% of MSE events were sustained at the next monthly assessment and participants spent 83-85% of remaining study follow-up in MSE Approximately 51% of participants with baseline MG-ADL scores of 6-10 and 21% of participants with baseline MG-
Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced a new post hoc analysis from the Phase 3 trial conducted in China by its collaborator,
Vor Biopharma: A Funded Replication Story With Franchise Potential
Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust liquidity position. Read why VOR stock is a buy.
Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
Recently published Sjogren's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Sjogren's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis
Topline results from UPSTREAM MG’s 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development across the myasthenia gravis (MG) spectrum; first patient dosing anticipated in the first half of 2027 BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the comple
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-24 | RA CAPITAL MANAGEMENT, L.P. | -1,500 | - | - |
| 2026-08-24 | RA CAPITAL MANAGEMENT, L.P. | +1,500 | $3.736 | $5,604 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P. | -2,100,000 | $5 | $10,500,000 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P. | -213 | $19.75 | $4,207 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P. | +2,100,000 | $0.002 | $4,200 |
| 2026-07-07 | ZACCARDELLI DAVID | +42,658 | - | - |
| 2026-06-11 | Joustra Wouter | +57,162 | - | - |
| 2026-06-11 | Levin Andrew David | +57,162 | - | - |
| 2026-06-11 | Detheux Michel | +57,162 | - | - |
| 2026-06-11 | Namouni Fouad | +56,549 | - | - |
| 2026-06-11 | Cumbo Alexander | +56,345 | - | - |
| 2026-06-11 | Beckman Daniella | +53,283 | - | - |
| 2026-06-11 | Kalir Erez | +57,162 | - | - |
| 2026-06-11 | RA Capital Healthcare Fund LP | +57,162 | - | - |
| 2026-04-22 | RA Capital Healthcare Fund LP | -165,150 | $15.77 | $2,604,416 |
| 2026-04-20 | RA Capital Healthcare Fund LP | -171,963 | $15.77 | $2,711,857 |
| 2026-04-17 | RA Capital Healthcare Fund LP | -458,411 | $16.28 | $7,462,931 |
| 2026-04-15 | RA Capital Healthcare Fund LP | -53,644 | $16.01 | $858,840 |
| 2026-04-14 | RA Capital Healthcare Fund LP | -153,735 | $15.97 | $2,455,148 |
| 2026-04-13 | RA Capital Healthcare Fund LP | -530,610 | $16.15 | $8,569,352 |
| 2026-04-10 | RA Capital Healthcare Fund LP | -828 | $15.75 | $13,041 |
| 2026-04-09 | RA Capital Healthcare Fund LP | -135,201 | $16.59 | $2,242,985 |
| 2026-04-08 | RA Capital Healthcare Fund LP | -130,862 | $16.91 | $2,212,876 |
| 2026-04-08 | RA Capital Healthcare Fund LP | -353,242 | $16.32 | $5,764,909 |
| 2026-04-06 | RA Capital Healthcare Fund LP | -6,775 | $18.5 | $125,338 |
| 2026-04-06 | RA Capital Healthcare Fund LP | -44,728 | $17.31 | $774,242 |
| 2026-04-06 | RA Capital Healthcare Fund LP | -537,754 | $16.51 | $8,878,319 |
| 2026-04-02 | RA Capital Healthcare Fund LP | -1,525 | $19.06 | $29,066 |
| 2026-04-02 | RA Capital Healthcare Fund LP | -258,475 | $18.23 | $4,711,999 |
| 2025-12-18 | Joustra Wouter | +3,000 | - | - |
| 2025-12-18 | Levin Andrew David | +3,000 | - | - |
| 2025-12-18 | RA Capital Healthcare Fund LP | +3,000 | - | - |
| 2025-12-18 | RA Capital Healthcare Fund LP | -4,625,346 | $10.81 | $49,999,990 |
| 2025-12-05 | Zuraw Qing Che | +218,652 | - | - |
| 2025-12-05 | Zuraw Qing Che | -218,652 | - | - |
| 2025-12-05 | Kress Jean-Paul | +4,164,831 | - | - |
| 2025-12-05 | Kress Jean-Paul | -4,164,831 | - | - |
| 2025-12-05 | Mahatme Sandesh | +1,388,274 | - | - |
| 2025-12-05 | Mahatme Sandesh | -694,137 | - | - |
| 2025-10-30 | RA Capital Healthcare Fund LP | -24,579 | $25.12 | $617,424 |
| 2025-10-29 | RA Capital Healthcare Fund LP | -251,518 | $25.22 | $6,343,284 |
| 2025-10-28 | RA Capital Healthcare Fund LP | -36,483 | $28.18 | $1,028,091 |
| 2025-10-28 | RA Capital Healthcare Fund LP | -87,828 | $27.1 | $2,380,139 |
| 2025-10-27 | RA Capital Healthcare Fund LP | -90,941 | $28.12 | $2,557,261 |
| 2025-10-24 | RA Capital Healthcare Fund LP | -53,345 | $28.01 | $1,494,193 |
| 2025-10-23 | RA Capital Healthcare Fund LP | -76,880 | $28.01 | $2,153,409 |
| 2025-10-21 | Hoffman Reid | -200 | $30.075 | $6,015 |
| 2025-10-21 | RA Capital Healthcare Fund LP | -25,027 | $28.11 | $703,509 |
| 2025-10-20 | Hoffman Reid | -11,616 | $30.0535 | $349,101 |
| 2025-10-20 | RA Capital Healthcare Fund LP | -1,287 | $30.12 | $38,764 |
| 2025-10-20 | RA Capital Healthcare Fund LP | -6,553 | $30.12 | $197,376 |
| 2025-10-20 | RA Capital Healthcare Fund LP | -13,817 | $29.63 | $409,398 |
| 2025-10-20 | RA Capital Healthcare Fund LP | -70,366 | $29.63 | $2,084,945 |
| 2025-10-17 | Hoffman Reid | -1,028 | $31 | $31,868 |
| 2025-10-17 | Hoffman Reid | -24,689 | $30.2207 | $746,119 |
| 2025-10-17 | RA Capital Healthcare Fund LP | -2,492 | $31 | $77,252 |
| 2025-10-17 | RA Capital Healthcare Fund LP | -12,691 | $31 | $393,421 |
| 2025-10-17 | RA Capital Healthcare Fund LP | -6,040 | $30.28 | $182,891 |
| 2025-10-17 | RA Capital Healthcare Fund LP | -30,758 | $30.28 | $931,352 |
| 2025-10-17 | RA Capital Healthcare Fund LP | -34,284 | $29.12 | $998,350 |
| 2025-10-17 | RA Capital Healthcare Fund LP | -174,594 | $29.12 | $5,084,177 |
| 2025-10-16 | Hoffman Reid | -2,021 | $30.4548 | $61,549 |
| 2025-10-16 | RA Capital Healthcare Fund LP | -4 | $31.35 | $125 |
| 2025-10-16 | RA Capital Healthcare Fund LP | -20 | $31.35 | $627 |
| 2025-10-16 | RA Capital Healthcare Fund LP | -3,108 | $30.36 | $94,359 |
| 2025-10-16 | RA Capital Healthcare Fund LP | -15,826 | $30.36 | $480,477 |
| 2025-10-16 | RA Capital Healthcare Fund LP | -21,804 | $29.32 | $639,293 |
| 2025-10-16 | RA Capital Healthcare Fund LP | -111,041 | $29.32 | $3,255,722 |
| 2025-10-15 | Hoffman Reid | -7,894 | $32.7733 | $258,712 |
| 2025-10-15 | Hoffman Reid | -48,910 | $32.0459 | $1,567,365 |
| 2025-10-15 | Hoffman Reid | -14,851 | $31.0496 | $461,118 |
| 2025-10-15 | RA Capital Healthcare Fund LP | -46 | $31.17 | $1,434 |
| 2025-10-15 | RA Capital Healthcare Fund LP | -234 | $31.17 | $7,294 |
| 2025-10-15 | RA Capital Healthcare Fund LP | -8,384 | $30.55 | $256,131 |
| 2025-10-15 | RA Capital Healthcare Fund LP | -42,699 | $30.55 | $1,304,454 |
| 2025-10-14 | Hoffman Reid | -33,668 | $30.3192 | $1,020,787 |
| 2025-10-13 | Hoffman Reid | -2,334 | $33.0873 | $77,226 |
| 2025-10-13 | Hoffman Reid | -19,672 | $32.3587 | $636,560 |
| 2025-10-10 | Hoffman Reid | -40,983 | $30.9673 | $1,269,133 |
| 2025-10-09 | Hoffman Reid | -15,042 | $32.4052 | $487,439 |
| 2025-10-09 | Hoffman Reid | -33,842 | $31.9181 | $1,080,172 |
| 2025-10-08 | Hoffman Reid | -14,336 | $34.3391 | $492,285 |
| 2025-10-08 | Hoffman Reid | -60,926 | $33.7536 | $2,056,472 |
| 2025-10-07 | Hoffman Reid | -27,624 | $33.8369 | $934,711 |
| 2025-10-06 | Hoffman Reid | -18,156 | $37.7743 | $685,830 |
| 2025-10-06 | Hoffman Reid | -34,847 | $37.1213 | $1,293,566 |
| 2025-10-06 | Hoffman Reid | -17,760 | $36.0018 | $639,392 |